Late-Stage Ophthalmic Asset Secured

Tarsus Pharmaceuticals (TARS) has acquired Alkeus Pharmaceuticals, gaining access to gildeuretinol acetate, a candidate for Stargardt disease (developmental code ALK-001). Currently without a brand name, it is a deuterated vitamin A formulation administered once daily. It works by slowing the rate at which toxic vitamin A dimers and bisretinoids are formed in the retina, thereby delaying retinal degeneration associated with ABCA4 mutations. This acquisition, which expands Tarsus's commercial base from ocular surface disease (with XDEMVY, a 0.25% lotilaner ophthalmic solution) to rare retinal diseases, is seen as a strategic move.

Phase 3 NORTHSTAR is Key to Value

Gildeuretinol is currently in a global, randomized, double-blind, placebo-controlled Phase 3 trial called NORTHSTAR (NCT07419334), with an expected start date of June 2026 and a primary completion date of October 2029. The interim analysis of the Phase 2 TEASE-1 trial, involving 50 patients, showed a 21% reduction in the rate of atrophic lesion growth over two years, with a p-value of less than 0.001. While the observed reduction rate was 28% based on the area of observation, the confirmatory trial's reproducibility is a key variable in determining the company's valuation, given its design, which is supplemented by natural history data. The FDA has granted gildeuretinol designations including Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease, but approval from the FDA, EMA, and PMDA is still pending, and an advisory committee meeting has not yet been scheduled.

$450 Million Upfront Payment Accelerates Risk

The upfront payment for the acquisition is $450 million, consisting of $270 million in cash and $180 million in Tarsus common stock. Milestone payments, linked to regulatory approval and the achievement of the first commercial sale, could reach up to $350 million, with additional royalties in the high single-digit percentage range on net sales. Therefore, the nominal transaction value is up to $800 million, excluding royalties, but the structure, with 40% of the upfront payment in stock, reduces cash burn while diluting existing shareholders. The global market for Stargardt disease treatments in 2025 is projected at $317.2 million, and is expected to reach $2.4 billion in 2032, suggesting significant potential for return on investment if the late-stage trial is successful.

Tinlarebant is the Leading Competitor

The most advanced competing product is tinlarebant (LBS-008), an oral RBP4 antagonist from Belite Bio (BLTE). In the Phase 3 DRAGON trial, involving 104 patients, tinlarebant reduced lesion growth by 36% compared to placebo, meeting the primary endpoint with a p-value of 0.0033. Belite Bio is expected to initiate the FDA New Drug Application process in the first half of 2026, putting it ahead of gildeuretinol in the regulatory timeline. Currently, there is no FDA-approved standard treatment for Stargardt disease, with management focusing on visual aids, light exposure control, and avoidance of excessive vitamin A intake, making first-to-market advantage significant. However, gildeuretinol, unlike tinlarebant, which reduces the delivery of vitamin A to the eye, selectively slows the formation of toxic dimers, which may reduce the risk of dark adaptation impairment and color vision abnormalities, making this a key point of clinical differentiation.